Vitamin K epoxide reductase complex subunit 1 (VKORC1)

Class

Vitamin K antagonist (anticoagulant)

Pathway

Coagulation cascade — inhibits synthesis of vitamin K-dependent clotting factors II, VII, IX, X

Vitamin K epoxide reductase complex subunit 1 (VKORC1) is an enzyme embedded in the liver's endoplasmic reticulum that recycles vitamin K into the form the body needs to activate several proteins of the coagulation cascade. Specifically, four clotting factors—II, VII, IX, and X—must undergo a chemical modification (gamma-carboxylation) that depends on reduced vitamin K as a cofactor. VKORC1 restores oxidized vitamin K back to its active, reduced state after each round of this reaction, sustaining a continuous supply. Inhibiting VKORC1 interrupts this recycling loop, so newly made clotting factors are secreted in an incompletely modified, functionally impaired form. Because these factors have finite lifespans in circulation, the anticoagulant effect builds gradually over days as active factor levels decline rather than acting immediately. This mechanism underlies vitamin K antagonist therapy, used broadly wherever reducing the blood's clotting tendency is clinically desirable—prevention of venous thromboembolism, stroke risk reduction in certain heart rhythm disorders, and protection of patients with mechanical heart valves or other conditions predisposing to pathological clot formation. Because the same pathway also activates natural anticoagulant proteins (C and S), the biology is a shared chokepoint rather than a one-sided lever, which has practical implications for how therapy is initiated and monitored.